Log in

Solid Biosciences Stock Price, News & Analysis (NASDAQ:SLDB)

$10.40
+1.05 (+11.23 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$9.56
Now: $10.40
$11.07
50-Day Range
$8.06
MA: $9.81
$11.64
52-Week Range
$4.32
Now: $10.40
$37.50
Volume555,730 shs
Average Volume339,289 shs
Market Capitalization$478.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.91
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLDB
CUSIPN/A
Phone617-337-4680

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.53 per share

Profitability

Net Income$-74,800,000.00

Miscellaneous

Employees111
Market Cap$478.40 million
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.


Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.05. View Solid Biosciences' Earnings History.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Solid Biosciences.

What price target have analysts set for SLDB?

8 Wall Street analysts have issued 1-year price objectives for Solid Biosciences' stock. Their forecasts range from $4.00 to $22.00. On average, they expect Solid Biosciences' stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 1.0% from the stock's current price. View Analyst Price Targets for Solid Biosciences.

What is the consensus analysts' recommendation for Solid Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

What are Wall Street analysts saying about Solid Biosciences stock?

Here are some recent quotes from research analysts about Solid Biosciences stock:
  • 1. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (9/28/2019)
  • 2. Chardan Capital analysts commented, "We thus now upgrade SLDB from Neutral to Buy, increasing our PT from $7.50 to $10, ahead of Solid’s anticipated IGNITE DMD data update later this year. The risks surrounding SGT-001 are well-known to the market, and any improvements in the market’s view of SGT-001 safety and/or efficacy (e.g. with the IGNITE DMD data update later this year) could lead to significant share price momentum. Recall, Solid has reported adverse events in prior patients dosed with SGT-001. Solid announced the FDA placed a clinical hold on the IGNITE trial after a patient experienced decreased platelet counts, evidence of complement activation and reduced blood cell counts." (8/16/2019)

Has Solid Biosciences been receiving favorable news coverage?

Press coverage about SLDB stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Solid Biosciences earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Solid Biosciences.

Are investors shorting Solid Biosciences?

Solid Biosciences saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 3,320,000 shares, a drop of 11.0% from the August 15th total of 3,730,000 shares. Based on an average daily trading volume, of 560,200 shares, the short-interest ratio is currently 5.9 days. Currently, 11.0% of the company's stock are short sold. View Solid Biosciences' Current Options Chain.

Who are some of Solid Biosciences' key competitors?

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include SUMMIT THERAPEU/S (SMMT), Exelixis (EXEL), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), Ocular Therapeutix (OCUL), Progenics Pharmaceuticals (PGNX), Selecta Biosciences (SELB), Amarin (AMRN), Micron Technology (MU) and SCYNEXIS (SCYX).

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the folowing people:
  • Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
  • Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
  • Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $10.40.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $478.40 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is http://www.solidbio.com/.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.


MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: Profit Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel